Repository logo
Log in(current)
Repository logoMIT Open ScholarshipDSpace@MIT
  1. Home
  2. MIT Open Access Articles
  3. MIT Open Access Articles
  4. Suppression of 19S proteasome subunits marks emergence of an altered cell state in diverse cancers

Suppression of 19S proteasome subunits marks emergence of an altered cell state in diverse cancers

Thumbnail Image
Download
Name

Tsvetkov-2016-Suppression of 19S proteasome su.pdf

Size

1.22 MB

Format

Adobe PDF

Checksum (MD5)

285763c68e0a696d048fabc706857309

Author(s)
Tsvetkov, Peter
•
Brune, Zarina
•
Thiru, Prathapan
•
Ghandi, Mahmoud
•
Santagata, Sandro
•
Whitesell, Luke
•
Sokol, Ethan Samuel
•
Jin, Dexter X.
•
Gupta, Piyush
•
Lindquist, Susan
more
Date Issued
December 2016
Journal
Proceedings of the National Academy of Sciences
Publisher
National Academy of Sciences (U.S.)
Citation
Tsvetkov, Peter et al. “Suppression of 19S Proteasome Subunits Marks Emergence of an Altered Cell State in Diverse Cancers.” Proceedings of the National Academy of Sciences 114, 2 (Janaury 2017): 382–387 © 2017 National Academy of Sciences
Version
Final published version
Abstract
The use of proteasome inhibitors to target cancer’s dependence on altered protein homeostasis has been greatly limited by intrinsic and acquired resistance. Analyzing data from thousands of cancer lines and tumors, we find that those with suppressed expression of one or more 19S proteasome subunits show intrinsic proteasome inhibitor resistance. Moreover, such proteasome subunit suppression is associated with poor outcome in myeloma patients, where proteasome inhibitors are a mainstay of treatment. Beyond conferring resistance to proteasome inhibitors, proteasome subunit suppression also serves as a sentinel of a more global remodeling of the transcriptome. This remodeling produces a distinct gene signature and new vulnerabilities to the proapoptotic drug, ABT-263. This frequent, naturally arising imbalance in 19S regulatory complex composition is achieved through a variety of mechanisms, including DNA methylation, and marks the emergence of a heritably altered and therapeutically relevant state in diverse cancers.
MIT Department
Broad Institute of MIT and Harvard
Massachusetts Institute of Technology. Department of Biology
Koch Institute for Integrative Cancer Research at MIT
Terms of Use
Article is made available in accordance with the publisher's policy and may be subject to US copyright law. Please refer to the publisher's site for terms of use.
Persistent DSpace Link
http://hdl.handle.net/1721.1/111198
DOI of Published Version
https://doi.org/10.1073/pnas.1619067114
Repository logo
PrivacyPermissionsAccessibilityContact us
Repository logo
Notify us about copyright concerns.